X

Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer September 18, 2015

Week in Review: The Latest from PhRMA.

Share This

week-in-reviewSmall Increase in Price Over Time:  A new analysis from SSR Health found that after rebates and discounts, brand-name prescription medicine prices rose just 0.7 percent in the second quarter from the previous year, debunking claims that medicine prices are skyrocketing. Check it out here.

340B Spotlight: The latest 340B Spotlight explores research that found most 340B hospitals provide little to below average levels of charity care, despite the fact that the program was created to help vulnerable patients access the medicines they need. Find out more about why low rates of charity care is just one of many reasons the 340B program needs reform.

Clinical Pathways: A new survey from CancerCare finds that most patients are unaware of clinical pathways, even after the term was defined. It also reveals the need for better information flow from providers to patients on treatment decisions. Learn more here.

Research and Hope Awards: The 2015 Research and Hope Awards recognized organizations and individuals that are changing the world of oncology research and care. Take a look at this guest post from some of the evening’s co-hosts for more about the awardees’ contributions.

Health coverage resources in Spanish: With Hispanic Heritage Month kicking off this week, PhRMA introduced new Access Better Coverage resources in Spanish to help patients learn more about health coverage and care. Take a look at this post for more information.

Medicare Monday: This week’s post highlights new research published in Health Affairs (coauthored by PhRMA) about how adherence in Medicare and Medicaid saves money.

Topics: 340B, Access Better Coverage